Novartis’s Q2 top-line showed resilience at flat growth (NB all revenue growth numbers at constant currency unless specified otherwise), delivering sales of $12.5bn. These numbers were ahead of our as well as consensus estimates, strongly driven by the outperformance of Cosentyx, Gilenya and oncology assets bought from GSK, offsetting the underperformance primarily of Afinitor and ophthalmology assets shifted to the pharma business (including Lucentis). The 5% volume growth was offset b
22 Jul 2016
Cosentyx and growth products underpin top-line outperformance
Sign up to access
Get access to our full offering from over 30 providers
Get access to our full offering from over 30 providers
Cosentyx and growth products underpin top-line outperformance
Novartis AG (0QLR:LON) | 0 0 0.7% | Mkt Cap: 208,186m
- Published:
22 Jul 2016 -
Author:
Kamla Singh -
Pages:
4
Novartis’s Q2 top-line showed resilience at flat growth (NB all revenue growth numbers at constant currency unless specified otherwise), delivering sales of $12.5bn. These numbers were ahead of our as well as consensus estimates, strongly driven by the outperformance of Cosentyx, Gilenya and oncology assets bought from GSK, offsetting the underperformance primarily of Afinitor and ophthalmology assets shifted to the pharma business (including Lucentis). The 5% volume growth was offset b